Trials / Completed
CompletedNCT00767221
Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Calliditas Therapeutics AB · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will investigate the effect of PL-56 on albumin leakage and renal function (glomerular filtration rate) in patients with IgA nephropathy. It will also assess the safety of treatment with PL-56.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Budesonide | 8 mg PL-56 once daily for six months |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2008-10-07
- Last updated
- 2009-04-21
Locations
3 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00767221. Inclusion in this directory is not an endorsement.